



Press Release – For Immediate Release

## **ERASMUS MC BIOMEDICAL FUND CO-FOUND AND FINANCES BIOTECH SPIN-OUT THEROSTEON**

Rotterdam, April 1, 2008 – the Erasmus MC Biomedical Fund is pleased to announce the successful spin-out and financing of a new biotech company, Therosteon B.V.

Therosteon is a spin-off company from the Erasmus University Medical Center in Rotterdam. Its goal is to further develop novel therapies for bone diseases. Therosteon's technology is based on a proprietary drug development platform, which enables the company to generate new drug targets and therapies for a variety of bone diseases, including osteoporosis and bone metastasis. Therosteon's scientific founder is Hans van Leeuwen, Professor at the Department of Internal Medicine of the Erasmus MC and expert in the field of bone diseases and vitamin D biology.

Therosteon secured start-up financing from the Erasmus MC Biomedical Fund. In addition, the company has received an incubator investment from the Technology Transfer Office of the Erasmus MC and is preparing for a larger financing round later this year.

### **About Erasmus MC Biomedical Fund**

The Erasmus MC Biomedical Fund is an independent venture capital fund focusing on early stage companies and (university) spin-outs in the biotechnology and biomedical field with a presence in the Rotterdam region. The fund targets companies that are developing commercially promising products and technologies in life sciences, including pharmaceuticals, biotechnology, information technology and other high technology opportunities that offer venture capital returns. Please visit [www.erasmusmcfund.nl](http://www.erasmusmcfund.nl)

---

Note for the editor: For further information please contact: Erasmus MC Biomedical Fund, Harm de Vries, telephone: +31 (0)6 – 53216339, e-mail: [hdevries@erasmusmcfund.nl](mailto:hdevries@erasmusmcfund.nl)